Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs Liquidia Corporation Common Stock (LQDA) Price & Performance

Edgewise Therapeutics Inc. Common StockTrade

Liquidia Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Edgewise Therapeutics Inc. Common Stock vs Liquidia Corporation Common Stock — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.13 (market cap $3.94B), while Liquidia Corporation Common Stock trades at $34.58 (market cap $2.40B). The key difference: Edgewise Therapeutics Inc. Common Stock is the larger of the two by market cap, and Edgewise Therapeutics Inc. Common Stock is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Liquidia Corporation Common Stock for 0 Days on average.

	EWTX	LQDA
Market Cap	$3.94B	$2.40B
Volume	810,104	2,857,547
Sector	Health	Health
52-Week High	$48.35	$91.03
52-Week Low	$14.89	$22.02
Typical Hold Time	0 Days	0 Days
Enterprise Value	$3.48B	$2.30B

View details →View details →

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EWTX

100% Buy0% Sell

Avg holding period · 0 Days

LQDA

62% Buy38% Sell

Avg holding period · 0 Days

Top news

Latest headlines on both assets

EWTX

View details →

LQDA

Bending Spoons jumps 41% as Berkshire Hathaway boosts stake; Antelope Enterprise and others also surge.Andrew Wynn · 11 hours agoBullish Liquidia shares jump 25% after settling patent lawsuits with United TherapeuticsProactive Investors · 19 hours agoBullish Liquidia settles patent dispute with United Therapeutics, stock jumps 42% despite $380M payout.24/7 Wall Street · 21 hours agoBullish View details →

About Edgewise Therapeutics Inc. Common Stock

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.

About Liquidia Corporation Common Stock

Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.